Article

Efficacy and Safety Are Key Factors When Selecting Breast Cancer Treatment

The safety profile and effectiveness of each therapeutic option are both important considerations to keep in mind when clinicians and patients weigh their breast cancer treatment options, according to one expert.

The safety profile and effectiveness of each therapeutic option are both important considerations to keep in mind when clinicians and patients weigh their breast cancer treatment options, according to Dr. Sara Hurvitz.

CURE® recently spoke with Hurvitz, an associate professor of medicine at the University of California, Los Angeles, who walked through different scenarios in which safety and efficacy of each option may be given more weight depending on a patient’s situation, ultimately leading to a treatment decision that is most beneficial to the patient.

Transcript:

Both efficacy and safety of a given therapeutic are equally important considerations when deciding which therapy to go on.

In some situations, the safety profile is going to be more critical. For example, when a patient requires therapy to be given for an extended period of time, we have to consider how that drug’s safety profile and side effect profile is going to allow the patient to interact in her life.

In the early-stage setting, where we’re giving, for example, chemotherapy for three to four months, the safety profile is going to be a little worse, but we are trying to improve the patient’s odds for a cure. So, we are more willing to take on that toxicity profile.

That said, in every situation, the patient needs to be an active participant who is engaged with the clinician in making the decision regarding what type of therapy he or she will decide to take.

Related Videos
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Bald Doctor.
Dr. Anna Arthur is the Director of the Medical Nutrition Science Program, as well as a tenure-track Assistant Professor in the Department of Dietetics and Nutrition at the University of Kansas Medical Center.
Dr. Ritu Salani, the Director of Gynecologic Oncology at the University of California, Los Angeles (UCLA), UCLA Health, and a board-certified gynecologic oncologist.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Image of Dr. Braun.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston.